What are the challenges and opportunities for the healthcare sector post-pandemic? Where might we see innovations that drive M&A growth?
4m
3m
How are top investors navigating the longest biotech bear market in almost 20 years?
29m
5m
After an historic run in 2020, the biotech sector had a difficult year with slower activity in 2021. The pendulum, however, may be ready to swing back the other way.
4m
The digital health market was challenging in 2021, despite the broader macro demand remaining very healthy. While the long term opportunity is clear, the sector is maturing and evolving, which makes it more difficult to pinpoint which strategies or vendors will prevail.
3m
What does it take to tackle the most perplexing orphan diseases? Ted W. Love, M.D., President and CEO, Global Blood Therapeutics (GBT), speaks with RBC Capital Markets’ Senior Biotechnology Analyst Gregory Renza, M.D. about having a mission and the drive to succeed on this episode of Pathfinders.
27m 3m
Our podcast series explores the fast-moving world of Biopharma and what the road ahead looks like for companies and investors in the sector.
Our specialty expertise, combined with outstanding execution, has resulted in recurring transactions for biopharma clients as we partner with them through each stage of their development and growth.
One of the world’s fastest-growing, top 10 investment banks
Deep sectoral and scientific expertise across the biopharma industry
Dedicated healthcare teams to structure and execute equity solutions
Global reach to connect and collaborate with ‘perfect-fit’ partners
Healthcare is in the midst of a revolution. From the challenges facing individual sectors to breakthrough innovations, gain the insights you need into the forces that are reshaping the industry.
Access market and industry insights, commentary and analysis from our expert team to gain the perspective you need to make the most informed decisions.
Get the latest insights from RBC Capital Markets delivered to your inbox.
